Definition and epidemiology
Hashimoto's thyroiditis (chronic lymphocytic thyroiditis) is an organ-specific autoimmune disease characterized by lymphocytic infiltration of the thyroid gland, formation of lymphoid follicles with germinal centers, and progressive destruction of thyroid follicular cells. It is the leading cause of primary hypothyroidism and goiter in iodine-replete populations.
- Female-to-male ratio approximately 8-10:1
- Peak incidence in the 30-60 year age range, though it occurs at any age including childhood
- Prevalence of positive anti-TPO antibodies in the general population is roughly 10-15%, higher in women
- Strong association with other autoimmune conditions (type 1 diabetes, celiac disease, vitiligo, pernicious anemia, Addison disease) as part of autoimmune polyendocrine syndromes
- Most common cause of hypothyroidism in iodine-sufficient areas
- Anti-TPO antibodies positive in up to 90-95% of patients
- Painless, firm, diffusely enlarged (or atrophic) goiter
- Can cause transient hyperthyroidism (hashitoxicosis) before hypothyroidism develops
- Associated with HLA-DR3/DR4/DR5 and other autoimmune diseases (T1DM, celiac, Addison)
- Levothyroxine is first-line treatment for overt hypothyroidism
- Rare long-term risk of thyroid (MALT) lymphoma with rapid goiter enlargement
- Histology shows lymphocytic infiltration with germinal centers and Hurthle cell change
Etiology and risk factors
The disease results from a combination of genetic susceptibility and environmental triggers that break immune tolerance to thyroid antigens.
- Genetic factors: HLA-DR3, HLA-DR4, and HLA-DR5 associations; polymorphisms in CTLA-4 and PTPN22 (shared with other autoimmune diseases)
- Family history: strong clustering; first-degree relatives have increased risk
- Female sex: estrogen effects on immune regulation and X-chromosome factors
- Iodine excess: high iodine intake can precipitate or worsen autoimmune thyroiditis
- Postpartum period: postpartum thyroiditis is a related entity in genetically predisposed women
- Other autoimmune disease: type 1 diabetes mellitus, celiac disease, Sjogren syndrome, systemic lupus erythematosus, Addison disease (seen in autoimmune polyglandular syndrome type 2)
- Down syndrome and Turner syndrome: increased prevalence
- Radiation exposure and certain drugs (interferon-alpha, amiodarone, lithium) can trigger or unmask thyroid autoimmunity
Pathophysiology
Loss of self-tolerance leads to a T-cell-mediated attack on thyroid follicular cells, with secondary antibody production.
- CD8+ cytotoxic T cells and cytokine-mediated apoptosis (Fas/FasL pathway) destroy thyrocytes
- CD4+ T cells drive a predominantly Th1 response, promoting cell-mediated cytotoxicity
- B cells produce anti-thyroid peroxidase (anti-TPO) antibodies (present in up to 90-95% of patients) and anti-thyroglobulin (anti-Tg) antibodies (present in 60-80%)
- These antibodies are markers of autoimmunity rather than the primary pathogenic mechanism, though anti-TPO can contribute to complement-mediated injury
- Progressive follicular destruction and fibrosis reduce functional thyroid tissue, causing a gradual decline in thyroid hormone output
- Two histologic/clinical patterns exist: a goitrous (hypertrophic) form with lymphocytic infiltration and lymphoid follicle formation, and an atrophic form with fibrosis and gland shrinkage
- Early in the disease, follicular disruption can cause transient release of stored hormone (brief hyperthyroid phase, "hashitoxicosis"), followed by the expected hypothyroid course
Clinical features
Onset is typically insidious, over months to years, and many patients are detected incidentally via screening labs or an enlarging goiter.
- Goiter: painless, diffuse, firm, rubbery, often with a pebbly or irregular surface; non-tender (contrasts with subacute thyroiditis)
- Some patients present with an atrophic gland and no palpable goiter
- Symptoms of hypothyroidism (develop as functional reserve declines): fatigue, cold intolerance, weight gain, constipation, dry skin, hair thinning, bradycardia, menstrual irregularities (menorrhagia), depression, cognitive slowing
- Transient hyperthyroid symptoms (hashitoxicosis) may occur early or during flares
- Many patients are asymptomatic/euthyroid at diagnosis, identified by antibody positivity or incidental goiter
- Rarely, significant lymphocytic infiltration causes thyroid pain or tenderness (painless course is typical, but a painful variant exists)
Diagnosis
Diagnosis combines clinical findings, thyroid function tests, and antibody titers; imaging and biopsy are reserved for specific indications.
Laboratory tests
- TSH: elevated in overt hypothyroidism; may be normal in subclinical/early disease
- Free T4: low in overt hypothyroidism, normal in subclinical disease
- Anti-TPO antibodies: positive in approximately 90-95% of patients; most sensitive marker
- Anti-thyroglobulin antibodies: positive in 60-80%; less specific
Imaging
- Thyroid ultrasound: not required for diagnosis but shows a diffusely hypoechoic, heterogeneous gland with micronodulation when performed for other reasons
- Radioiodine uptake scanning has no routine diagnostic role
Biopsy
- Fine-needle aspiration is not needed for diagnosis; reserved for suspicious nodules to exclude malignancy (lymphocytic infiltrate seen incidentally)
| Test | Early/subclinical | Overt hypothyroidism |
|---|---|---|
| TSH | Normal or mildly elevated | Elevated |
| Free T4 | Normal | Low |
| Anti-TPO | Positive | Positive |
Differential diagnosis
- Graves disease: hyperthyroidism, diffuse goiter with bruit, TSH-receptor antibodies positive, increased radioiodine uptake (versus low/patchy uptake or hashitoxicosis in Hashimoto's)
- Subacute (de Quervain) thyroiditis: painful, tender thyroid, post-viral, elevated ESR, self-limited
- Silent (painless) and postpartum thyroiditis: transient thyrotoxicosis followed by hypothyroidism, often antibody-positive but typically resolves
- Riedel thyroiditis: rare, fibrosing, hard "woody" thyroid that can invade adjacent structures
- Simple/multinodular goiter: no antibody positivity, normal thyroid function
- Thyroid lymphoma: rare but important; consider with rapidly enlarging goiter in a patient with longstanding Hashimoto's
- Iodine deficiency goiter: endemic, antibody-negative
- Drug-induced thyroiditis (amiodarone, lithium, interferon, immune checkpoint inhibitors): temporal relationship to drug exposure
Management
Treatment is guided by thyroid function, not by antibody titers alone; antibody-positive but euthyroid patients generally do not require treatment but warrant monitoring.
Overt hypothyroidism
- Levothyroxine (synthetic T4) is first-line and the standard of care per American Thyroid Association and European Thyroid Association guidelines
- Dosed to normalize TSH into the reference range; taken on an empty stomach, separated from calcium, iron, and proton pump inhibitors which impair absorption
- Lifelong therapy in most cases given the progressive, destructive nature of the disease
Subclinical hypothyroidism
- Treatment is individualized; generally recommended if TSH is markedly elevated (commonly cited threshold around 10 mIU/L), if the patient is symptomatic, pregnant or planning pregnancy, or has positive antibodies with risk factors (e.g., infertility, dyslipidemia)
- Guidelines vary on the exact threshold for mild elevations in asymptomatic patients; shared decision-making is recommended
Pregnancy
- Closer TSH monitoring and lower treatment thresholds given risks of adverse obstetric and fetal neurodevelopmental outcomes; dose typically needs to increase during pregnancy
Goiter without hypothyroidism
- Monitor; surgery considered only for compressive symptoms, cosmetic concern, or suspicious nodules
General
- No evidence supports selenium, iodine supplementation, or dietary interventions (e.g., gluten-free diet without confirmed celiac disease) as standard therapy; selenium has mixed, generally low-quality evidence and is not routinely recommended
- Periodic TSH monitoring (e.g., annually, or 4-6 weeks after dose changes)
Complications and prognosis
- Progression from subclinical to overt hypothyroidism occurs in a substantial proportion of antibody-positive patients over time
- Myxedema coma: rare, life-threatening decompensated hypothyroidism, usually precipitated by infection, cold exposure, or sedative use in longstanding untreated disease
- Increased risk of other autoimmune endocrinopathies (type 1 diabetes, Addison disease, premature ovarian insufficiency) and celiac disease
- Modest increased risk of primary thyroid lymphoma (mucosa-associated lymphoid tissue type) over decades; suspect with rapid goiter growth
- Possible mild association with papillary thyroid carcinoma, though this remains debated
- With adequate levothyroxine replacement, prognosis is excellent and patients can expect a normal lifespan and quality of life
- Untreated maternal hypothyroidism in pregnancy increases risk of miscarriage, preterm birth, and impaired fetal neurodevelopment
HASHIMOTO: Hypothyroid symptoms, Anti-TPO/Anti-Tg antibodies, Slow (insidious) onset, HLA-DR3/4/5 association, Immune (T-cell) mediated, Myxedema risk if untreated, Other autoimmune diseases coexist, Thyroid goiter (firm, painless), Overactive phase possible early (hashitoxicosis).
Practice questions
1. A 42-year-old woman presents with fatigue, cold intolerance, and a 6-month history of gradual weight gain. Examination reveals a diffusely enlarged, firm, non-tender thyroid gland. TSH is 18 mIU/L (elevated) and free T4 is low. Which of the following is most likely to be positive in this patient?
2. A 35-year-old woman with known Hashimoto's thyroiditis on stable levothyroxine therapy notices her previously stable goiter has rapidly enlarged over the past 2 months, with new hoarseness and difficulty swallowing. What is the most appropriate next step?
3. A 29-year-old woman at 10 weeks of pregnancy has a TSH of 6.5 mIU/L (reference range 0.4-4.0) with positive anti-TPO antibodies and no prior thyroid history. She reports mild fatigue. Which of the following is the most appropriate management?
Frequently asked questions
What causes Hashimoto's thyroiditis?
Hashimoto's thyroiditis is caused by an autoimmune attack on the thyroid gland in genetically susceptible individuals, triggered by factors such as high iodine intake, pregnancy, or other autoimmune disease. T cells destroy thyroid follicular cells while B cells produce anti-TPO and anti-thyroglobulin antibodies. The exact trigger varies, but genetic predisposition (HLA-DR3/4/5) combined with environmental factors is the accepted model.
What are the first symptoms of Hashimoto's thyroiditis?
The earliest sign is often a painless, firm goiter noticed on exam, sometimes before any symptoms appear. As thyroid function declines, patients develop fatigue, cold intolerance, weight gain, constipation, dry skin, and menstrual irregularities. Some patients briefly experience mild hyperthyroid symptoms (palpitations, anxiety) early in the disease before hypothyroidism sets in.
How is Hashimoto's thyroiditis diagnosed?
Diagnosis is based on elevated TSH with low or normal free T4 plus positive anti-TPO (and often anti-thyroglobulin) antibodies. A firm, diffusely enlarged thyroid on exam supports the diagnosis. Ultrasound and biopsy are not required unless a suspicious nodule is present; they are not standard diagnostic tools for Hashimoto's itself.
Is Hashimoto's thyroiditis curable?
No, Hashimoto's thyroiditis is not curable, but it is very manageable. Once hypothyroidism develops, lifelong levothyroxine replacement controls symptoms and normalizes thyroid hormone levels effectively. The underlying autoimmune process persists, but with treatment most patients live a normal, healthy life without disease-related complications.
Hashimoto's thyroiditis vs Graves disease — what is the difference?
Hashimoto's thyroiditis causes hypothyroidism through autoimmune gland destruction, while Graves disease causes hyperthyroidism through TSH-receptor-stimulating antibodies. Hashimoto's presents with a firm, non-tender goiter and anti-TPO antibodies, whereas Graves features a diffuse goiter with bruit, eye signs (exophthalmos), and TSH-receptor antibodies. Both are autoimmune and can coexist or transition between phases in the same patient.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E06.3
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.